Stock · NSE
BIOCON
410.10▲ 6.55 (1.62%)Last 2 days · 15m candles10/7/2026, 20:03:52
Open: 403.85High: 410.15Low: 400.10Prev: 403.55
VERIFIEDMint Companies·4d★ ON YOUR LIST
True North cashes out $2 billion for investors as PE firms step up exitsAI summary· POSITIVE
- ·True North has returned $2 billion to investors.
- ·This return is attributed to exits from several portfolio companies.
- ·Exited companies include FedFina, Niva Bupa, Biocon Biologics, Infinity Fincorp Solutions, Zydus Wellness, and Home First Finance.
VERIFIEDET Markets·4d★ ON YOUR LIST
Analysts back buy-on-dips strategy as Nifty targets 24,450–24,800AI summary· POSITIVE
- ·Analysts suggest a buy-on-dips strategy for the Nifty around the 24,000-24,150 range.
- ·Potential upside targets for the Nifty are projected to reach 24,800.
- ·Several stocks, including Container Corporation of India and IndusInd Bank, are recommended with specific price targets.
VERIFIEDET Stocks·4d★ ON YOUR LIST
Analysts back buy-on-dips strategy as Nifty targets 24,450–24,800AI summary· POSITIVE
- ·Analysts anticipate the Nifty to continue its upward trend.
- ·They suggest buying on dips around the 24,000-24,150 mark.
- ·Potential upside targets for the Nifty are seen reaching 24,800.
VERIFIEDEconomic Times News·4d★ ON YOUR LIST
Analysts back buy-on-dips strategy as Nifty targets 24,450–24,800AI summary· POSITIVE
- ·Analysts suggest a buy-on-dips strategy for the Nifty around the 24,000-24,150 range.
- ·Potential upside targets for the Nifty are projected to reach 24,800.
- ·Several stocks, including Container Corporation of India and IndusInd Bank, are recommended with specific price targets.
Google News, SEBI·14d★ ON YOUR LIST
Supreme Court upholds SAT relief for former Biocon executive in insider trading case - The New Indian ExpressVERIFIEDMint Markets·17d★ ON YOUR LIST
Buy or sell: Gift Nifty signals gap-up opening, Vaishali Parekh recommends three stocks to buy today — 23 June 2026AI summary· NEUTRAL
- ·Gift Nifty signals a gap-up opening for the Indian stock market.
- ·Vaishali Parekh has recommended three stocks for trading today.
- ·The recommended stocks are Hindustan Zinc, Biocon, and Adani Green Energy.
VERIFIEDET Stocks·18d★ ON YOUR LIST
Laurus Labs, Biocon, Ather Energy, Lenskart among probable MSCI India Standard Index inclusion candidates, says JM FinancialAI summary· NEUTRAL
- ·JM Financial expects Laurus Labs and Biocon to be added to the MSCI India Standard Index.
- ·Ather Energy and SAIL are considered medium-probability candidates for inclusion.
- ·SBI Card has a high probability of being excluded from the index.
VERIFIEDET Markets·18d★ ON YOUR LIST
Laurus Labs, Biocon, Ather Energy, Lenskart among probable MSCI India Standard Index inclusion candidates, says JM FinancialAI summary· NEUTRAL
- ·JM Financial expects Laurus Labs and Biocon to be added to the MSCI India Standard Index.
- ·Ather Energy and SAIL are considered medium-probability candidates for inclusion.
- ·SBI Card has a high probability of being excluded from the index.
VERIFIEDMint Companies·24d★ ON YOUR LIST
Biocon eyes crown of world’s top insulin supplier amid rush for GLP-1AI summary· NEUTRAL
- ·Biocon is currently the third-largest insulin supplier globally by volume.
- ·The company has significantly invested in increasing its production capacity.
- ·Chairperson Kiran Mazumdar-Shaw highlighted the company's focus on insulin supply amidst the demand for GLP-1 drugs.
VERIFIEDET Finance·24d★ ON YOUR LIST
Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for BioconAI summary· POSITIVE
- ·Biocon aims to become the world's top insulin supplier within five years.
- ·The company is currently the third-largest global insulin provider.
- ·Biocon is expanding its production capacity to meet growing demand.
VERIFIEDET Finance·31d★ ON YOUR LIST
Insider trading: Supreme Court upholds SAT clearance to Biocon MDVERIFIEDMint Markets·50d★ ON YOUR LIST
Gland Pharma to Biocon: Pharma stocks rally up to 27% in a month: Can they shield portfolio from US-Iran war-led risks?AI summary· POSITIVE
- ·The Nifty Pharma index has risen by approximately 11% in the last month.
- ·The Nifty Pharma index has outperformed the Nifty 50, which saw a 3.6% decline in the same period.
- ·Year-to-date, the Nifty Pharma index has gained 9.4%, while the Nifty 50 has fallen by an equal margin.
VERIFIEDET Markets·58d★ ON YOUR LIST
Technical stock picks! 3 shares that could give up to 15% return this May. Do you own any?AI summary· POSITIVE
- ·Nifty has seen a rally following a recent downtrend.
- ·Analysts suggest a buy-on-dips strategy for the Nifty.
- ·KEI Industries, Grasim Industries, and Biocon are highlighted as potential stock picks with up to 15% upside for May.
VERIFIEDET Markets·59d★ ON YOUR LIST
Tata Consumer among 5 F&O stocks with a sharp rise in futures open interestAI summary· NEUTRAL
- ·Five NSE F&O stocks saw significant increases in futures open interest on May 11.
- ·These stocks included Dalmia Bharat, Tata Consumer Products, Kaynes Technology India, Bharti Airtel, and Biocon.
- ·The rise in open interest indicates increased trader participation and fresh positioning.
VERIFIEDET Stocks·59d★ ON YOUR LIST
Tata Consumer among 5 F&O stocks with a sharp rise in futures open interestAI summary· NEUTRAL
- ·Five NSE F&O stocks saw significant increases in futures open interest on May 11.
- ·These stocks included Dalmia Bharat, Tata Consumer Products, Kaynes Technology India, Bharti Airtel, and Biocon.
- ·The rise in open interest indicates increased trader participation and new positioning.
VERIFIEDMint Companies·63d★ ON YOUR LIST
Biosimilar ramp-up to drive growth for Biocon in FY27AI summary· POSITIVE
- ·Biocon's recently launched biosimilars are scaling up across markets.
- ·This ramp-up is expected to gather momentum throughout the year.
- ·The growth is particularly anticipated in the second half of FY27.
VERIFIEDET Finance·63d★ ON YOUR LIST
Biocon shifts focus to margins, capacity utilisation after expansion phaseAI summary· NEUTRAL
- ·Biocon is prioritizing capacity utilization and margin expansion after global investments.
- ·The company reported a 13% revenue increase for FY26, but net profit declined.
- ·Biocon is exploring in-licensing for its biosimilars and focusing on profitable growth.